Position paper 22 Oct 2020

Position Paper – Best Practices for In-Country Testing and Sample Management

In this paper, IFPMA will describe challenges faced by Industry for in-country testing and provide recommendations for more efficient management of samples.

Press release 22 Oct 2020

IFPMA launches Note for Guidance to help those acting on behalf of biopharmaceutical companies live up to its ethical business principles

GENEVA, 22 October 2020: The International Association of Pharmaceutical Manufacturers and Associations (IFPMA) published today a Note for Guidance on how to foster ethical relationships with third party intermediaries in the biopharmaceutical sector. IFPMA’s mission rests on the establishment and promotion of ethical principles for the industry as a whole and anyone acting on its...

Expert insight 19 Oct 2020

Stimulating innovation in Africa, supporting the emergence of new technologies

On Saturday October 17, I was honoured to take part in the 8th edition of the African Invention and Technological Innovation Fair organized by the Organisation Africaine sur la Propriété Intellectuelle (OAPI). Innovation, creativity and intellectual property are linked to socio-economic development. The African Invention and Technology Innovation Fair plays a key role in stimulating...

Statement 16 Oct 2020

IFPMA statement on Intellectual Property and COVID-19

The biopharmaceutical industry has made addressing the pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments, diagnostics and vaccines at unprecedented pace, while committing to and engaging in unprecedented levels of international collaboration and coordination through initiatives such as ACT-A, ACTIV and CEPI to ensure equitable access to products being developed.

Video 15 Oct 2020

2020: a game changer year for AMR? (Video)

At the AMR Congress 2020, Dame Sally Davies, UK AMR Special Envoy asked Thomas Cueni, IFPMA’s Director General, if industry has done enough to tackle AMR and what remains to be done to create a sustainable market and long-term R&D investment into antibiotics.

Statement 13 Oct 2020

Biopharmaceutical industry support EU regulators exceptional transparency measures and call other regulatory authorities to follow suit to help ensure confidence in the science and the decision-making

Geneva, 13 October 2020: IFPMA & EFPIA support European Medicines Agency’s (EMA) initiative to implement exceptional transparency measures that are targeting regulatory activities for the assessment and approval of medicines and vaccines for COVID-19.[1] The biopharmaceutical industry represented by IFPMA and EFPIA encourage other national regulatory authorities to follow EMA’s example. The European Medicines Agency...

Press release 13 Oct 2020

IFPMA applauds APEC for trailblazing efforts to demonstrate return on ethics for SMEs through Vision 2025

GENEVA, 13 October 2020: Today, IFPMA joined hundreds of diverse stakeholders from more than 30 economies spanning the Asia-Pacific and beyond in a shared commitment to solidify and grow the world’s largest public-private, multi-sectoral partnership in the advancement of business ethics in the medical device and biopharmaceutical sectors, through Vision 2025. This roadmap builds on...

Expert insight 13 Oct 2020

Supporting the emergence of a new generation of industry leaders for sustainable global health

Since the beginning of the COVID-19 crisis, innovative players and industries operating in the health sector have been pressed to collaborate, innovate, and accelerate their research and development efforts in response to these unprecedented times. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the trade association that represents biopharmaceutical companies around the world, has...

Expert insight 9 Oct 2020

5 Questions… to Wendy Orchard on mental health & COVID-19

In the lead up to World Mental Health Day we sat down with Wendy Orchard, Executive Director of the International Association for Suicide Prevention (IASP) as she prepares to hold a virtual March for mental health, to find out what has been the impact of COVID-19 on mental health and what are the global efforts...

Statement 6 Oct 2020

IFPMA Statement for the Special session of the Executive Board on implementation of Resolution WHA73.1

COVID-19 is a human, social, and economic tragedy that, as of September 2020, has cost more than a million lives globally and is estimated to contract global GDP by $US 7 trillion in 2020. Since the early days of this pandemic, the R&D-based biopharmaceutical industry has responded through many initiatives aimed at providing and prioritizing...

Position paper 5 Oct 2020

Ethical third party intermediary relationships in the biopharmaceutical sector

To ensure and improve ongoing access for patients and HCPs to innovative, reliable, and effective medicines and vaccines, it is often necessary for research and development-based biopharmaceutical manufacturers (“Companies”) to contract with third parties to support their business activities. These third parties can operate as clinical research organizations, distributors, wholesalers, distribution or sales agents, consultants,...

Video 5 Oct 2020

5 lessons as COVID-19 unfolds for future pandemics – Insights from the biopharmaceutical industry

Thomas Cueni, Director General of IFPMA, participated in the Science and Technology in Society Forum (STS Forum) on 4th October 2020, in a session titled “Improving Preparedness for Pandemic Diseases: the Role of Science and Technology”. Other speakers included PeggyHamburg (former Commissioner, US FDA, Prof. Yamanaka (Nobel Laureate 2012), and Prof. Tan from (Ministry of...